BEIJING, Dec. 18, 2025 /PRNewswire/ -- Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully completed its Series A and A+ ...

Syneron Medical Ltd. and Candela Corporation to Merge Creating a Leading Global Aesthetic Device Company Combination of Syneron and Candela creates the most comprehensive aesthetic device product ...

BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader ...

IRVINE, Calif. and LONDON, April 3, 2017 /PRNewswire/ — Syneron Medical Ltd. (NASDAQ: ELOS), a leading global non-surgical aesthetic device company, and Apax Partners, a leading global private equity ...

Louis P. Scafuri, Chief Executive Officer of Syneron, commented, "During the second quarter we achieved strong financial results, including our third consecutive quarter with record revenue. Strong ...

Syneron Medical has put a familiar person on its CEO throne. The company named Shimon Eckhouse as its new chief executive, effective immediately. He succeeds Louis Scafuri, who will "remain available" ...

Israel-based Syneron and Palomar settled the case just three weeks before it was due to go before a Massachusetts court. Syneron has agreed to pay Palomar Medical Technologies $31 million in cash and ...

Apax Partners LLC has agreed to buy Syneron Medical Ltd. for $397 million in cash. Syneron Medical—also known as Syneron Candela—is based in Israel and maintains a U.S. headquarters in Irvine under ...

Sept 9 (Reuters) - Aesthetic laser device maker Syneron Medical Ltd said it agreed to buy rival Candela Corp in an all-stock deal, valued at about $65 million. Sign up here. Maxim Group analyst ...